Docket #0950 Date Filed: 09/01/2026

CLERK, U.S. BANKRUPTCY COURT
NORTHERN DISTRICT OF TEXAS

ENTERED

THE DATE OF ENTRY IS ON
THE COURT'S DOCKET

The following constitutes the ruling of the court and has the force and effect therein described.

Signed September 1, 2026

United States Bankruptcy Judge

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE NORTHERN DISTRICT OF TEXAS
DALLAS DIVISION

In re:	§	**Chapter 11**
	§	
EIGER BIOPHARMACEUTICALS, INC., *et al.*[1]	§	**Case No. 24-80040 (SGJ)**
	§	
	§	
Debtors.	§	**(Jointly Administered)**

ORDER EXTENDING THE DEADLINE TO OBJECT TO CLAIMS

Upon the motion (the "Motion")[2] of Dundon Advisers, LLC in its capacity as the Liquidating Trustee (the "Liquidating Trustee", "Movant") for an order extending the deadline by which a Claims Objection must be made by 60 days, through and including September 18, 2026, without prejudice to Movant's right to seek additional extensions thereof, all as more fully set forth in the Motion; and the Court having jurisdiction to consider the Motion and the relief requested therein pursuant to 28 U.S.C. § 1334; and consideration of the Motion and the requested relief

[1] The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors' service address is 2100 Ross Ave., Dallas, Texas 75201.

[2] Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Motion.

24800402609010000000000001

being a core proceeding pursuant to 28 U.S.C. § 157(b); and venue being proper before the Court pursuant to 28 U.S.C. §§ 1408 and 1409; and due and proper notice of the Motion having been provided; and such notice having been adequate and appropriate under the circumstances, and it appearing that no other or further notice need be provided; and the Court having reviewed the Motion; and the Court having determined that the legal and factual bases set forth in the Motion establish just cause for the relief granted herein; and upon all of the proceedings had before the Court and after due deliberation and sufficient cause appearing therefor, IT IS HEREBY ORDERED THAT:

1. The Claims Objection Deadline is hereby extended to 5:00 p.m. (Prevailing Central Time) on September 18, 2026.

2. This Court shall retain jurisdiction with respect to all matters arising from or related to the implementation or interpretation of this Order.

End of Order

Submitted by:

MCKOOL SMITH, PC

John J. Sparacino (SBN 18873700)
S. Margie Venus (SBN 20545900)
600 Travis Street, Suite 7000
Houston, Texas 77002
Telephone: (713) 485-7300
Facsimile (713) 485-7344
jsparacino@mckoolsmith.com
mvenus@mckoolsmith.com

Patrick W. Pijls (SBN 24118501)
300 Crescent Court, Suite 1200
Dallas, Texas 75201
Telephone (214) 978-4000
Facsimile (214) 978-4044
ppijls@mckoolsmith.com

-and-

PORZIO, BROMBERG & NEWMAN, P.C.
Warren J. Martin Jr. (admitted *pro hac vice*)
Rachel A. Parisi (admitted *pro hac vice*)
5 Sylvan Way
P.O. Box 218
Parsippany, NJ 07054
Telephone: (973) 538-4006
Facsimile: (973) 538-5146
WJMartin@pbnlaw.com
RAParisi@pbnlaw.com

Counsel to Dundon Advisers, LLC, as Liquidating Trustee of the Eiger BioPharmaceuticals Liquidating Trust